Merck KGaA, Darmstadt, Germany to Expand US Biopharmaceutical R&D Facility to Advance Innovative Clinical Pipeline

Date Published02/06/2019
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name EMD Serono
Parent companyMerck KGaA
Reshoring category:Foreign Direct Investment
Year reshoring announced:2019
Year reshoring implemented or to be implemented:2021
Capital investment ($):70
Country(ies) from which reshored:Germany
City reshored to:Billerica
State(s) reshored to:MA
If relevant, work nearshored to:-
Product(s) reshoredpharmaceuticals
What domestic positive factors made reshoring more attractive?Customer responsiveness improvement, Skilled workforce availability/training
Find Reshoring Articles